Physician profile
John Michael Zerfing
NPI 1992303895
$1,178.19
in general payments reported to CMS, 2019-2025
28 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2022: $250 · 2023: $126 · 2024: $170 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.33 |
| Education | $175.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $173.85 | 2021-2025 | Enhertu, Lynparza, Imfinzi |
| Astellas Pharma US INC | $140.27 | 2022-2024 | Xospata |
| Genentech USA, INC. | $135.14 | 2025 | Tecentriq, Polivy, Itovebi |
| Pfizer INC. | $97.64 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $93.50 | 2022 | |
| Accord Healthcare, INC. | $88.67 | 2025 | |
| Janssen Biotech, INC. | $57.81 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.88 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $32.06 | 2023-2024 | Tavalisse, Rezlidhia |
| Daiichi Sankyo INC. | $25.87 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $25.44 | 2022 | |
| Beigene USA, INC. | $24.95 | 2023 | Brukinsa |
| Emd Serono, INC. | $23.75 | 2021-2022 | |
| Iovance Biotherapeutics, INC. | $20.74 | 2025 | Amtagvi |
| Morphosys, US INC. | $19.44 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $18.35 | 2025 | Monoferric |
| Genzyme Corporation | $13.99 | 2023 | |
| Array Biopharma INC | $13.84 | 2023 | Xalkori, Lorbrena, Braftovi |
| Abbvie INC. | $13.51 | 2025 | |
| Adc Therapeutics America, INC. | $13.18 | 2023 | |
| Fresenius Kabi USA, LLC | $13.11 | 2024 | Stimufend |
| Alexion Pharmaceuticals, INC. | $13.07 | 2024 | Ultomiris |
| Eusa Pharma (US) LLC | $12.47 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $12.00 | 2021 | |
| Aveo Pharmaceuticals, INC. | $11.91 | 2021 | |
| Acrotech Biopharma INC. | $11.84 | 2021 | |
| Tersera Therapeutics LLC | $11.63 | 2021 | |
| Seagen INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Zerfing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.